I
nflammation represents a critical and unifying driving force promoting atherosclerotic plaque progression. Macrophages and T lymphocytes modulate lesion growth, by releasing cytokines and growth factors, as suggested by the in vivo angiogenic properties of some of these secreted factors. 1 Early studies demonstrated that T cells infiltrating the atherosclerotic plaque release interleukin (IL)-3 [1] [2] [3] and basic fibroblast growth factor (bFGF), both promoting in vivo new vessel formation. 3, 4 These observations sustain the possibility that, in concert with bFGF or with other soluble factors, IL-3 may contribute to plaque progression. Moreover, as recently demonstrated, like IL-3, 4 bFGF induces vascular endothelial morphogenesis by activating the signal transducer and activator of transcription (STAT)5A signaling pathway. 5 The STAT5 transcription factors migrate into the nucleus and regulate the expression of genes involved in different cell functions, including cell proliferation and cell migration. 6 In particular, despite their high degree of conservation, several lines of evidence indicate that the 2 homologous proteins, STAT5A and STAT5B, exert nonredundant functions in the cardiovascular system. [7] [8] [9] See accompanying article on page 1500
New vessel formation is controlled by a complex network of genes. microRNAs (miRNAs) have recently come into focus as powerful players that control gene expression posttranscriptionally. 10 -13 miRNAs are short noncoding RNAs that negatively regulate gene expression, acting on their target mRNAs, in a tissue-and cell type-specific manner. 10 miRNA profiles on endothelial cells (ECs) revealed the presence of specific miRNAs, such as miRNA-17-5p (miR-17-5p), miR-21, miR-126, miR-210, miR-221/222, and miR-296, involved in the regulation of angiogenesis. 10 -13 In particular, the miR-221/miR-222 family seems to negatively modulate angiogenesis by targeting the c-Kit receptor. 14 More recently, p27 Kip1 and p57 Kip2 have also been identified as target genes involved in miR-221/miR-222-induced smooth muscle cell (SMC) proliferation. 15 The present study aimed to investigate the contribution of miR-221/222 in inflammation-mediated neoangiogenesis and their potential involvement in atherosclerotic intraplaque neovascularization.
Materials and Methods

Cell Cultures and Cell Proliferation Assay
ECs were isolated from a human umbilical vein and cultured as previously described. 4 To perform the experiments, ECs were synchronized to quiescent state by serum starvation for 12 hours (overnight), then the cells were cultured in the presence of 1% bovine calf serum, untreated or treated for 24 hours to 48 to 72 hours with IL-3 (20 ng/mL) or with bFGF (10 ng/mL). Cell viability was evaluated by trypan blue at the end of each experiment, and proliferative activity was assayed by direct cell count, by 3 individual operators in triplicate, as previously described. 1 Proliferation was evaluated by time-course experiments (24, 48, and 72 hours). Forty-eight hours of IL-3 and bFGF stimulation was used throughout the study. In selected experiments, untreated, bFGF-treated (data not shown), or IL-3-treated ECs were transiently transfected with premiR negative control, pre-miR-125a-3p, pre-miR-222, pre-miR-221, or pre-miR-126 precursor oligonucleotides or alternatively with anti-miR negative control, anti-miR-221, or anti-miR-222 inhibitor oligonucleotides (Applied Biosystems), according to manufacturer's recommendation, and analyzed 48 hours later.
RNA Isolation and Quantitative Real-Time PCR (qRT-PCR) for miRNAs Expression
Total RNA was isolated using TRIzol Reagent (Invitrogen) from untreated or treated cells, as indicated, and from human arterial samples-or Matrigel plug-derived ECs, following manufacturer's instructions. The expression of miR-17-5p, miR-21, miR-125a-3p, miR-126, miR-210, miR-221, miR-222, and miR-296 in different experimental conditions was evaluated using the TaqMan miRNA assay kit (Applied Biosystems). Single-stranded cDNA was synthesized from 50 ng of total RNA using looped primers of the TaqMan miRNA assay and TaqMan miRNA reverse transcription kit (Applied Biosystems). Each cDNA generated was amplified by qRT-PCR using sequence-specific primers from TaqMan miRNA assay in the ABI PRISM 7700 Sequence detection system (Applied Biosystems). miRNA expression was normalized to small nuclear RNA, RNU6B.
Reagents and antibodies, EC migration assay, qRT-PCR for STAT5A expression, Northern blot analysis, Western blot analysis, luciferase miRNA target reporter assay, endogenous depletion of STAT5A by small interfering RNAs, in vivo experiments, immunofluorescence analysis, isolation of ECs from Matrigel plugs, human arterial samples and isolation of vascular cells, statistical analysis, and an extended version of cell cultures and cell proliferation assay were described in detail in the supplemental section, which is available online at http://atvb.ahajournals.org.
Results
miRNA Expression in ECs Exposed to Inflammatory Stimuli
T cell-derived cytokine IL-3, like bFGF, 1,2 acts as an inflammatory angiogenic mediator. 3, 4 To evaluate the biological functions of miRNAs in inflammatory angiogenesis, a subset of 7 miRNAs, previously known to be involved in angiogenesis, 10 -13 was investigated by qRT-PCR. To this end, ECs were exposed or not (quiescent) to IL-3 or bFGF ( Figure 1A ). Consistent with previous reports, high expression of miR-17-5p, miR-21, miR-126, miR-210, miR-221, miR-222, and miR-296 was found in quiescent ECs, whereas a significant down-regulation of miR-296, miR-126, and miR-221/222 was detected in ECs challenged with both IL-3 and bFGF. No change in miR-17-5p, miR-21, and miR-210 expression was observed either after IL-3 and bFGF stimulation ( Figure 1A ). Further validation of some of them was obtained by Northern blot analysis (supplemental Figure I) , thus suggesting that angiogenic inflammatory stimuli might share a common miRNA signature ( Figure 1A ). To verify the biological relevance of miR-126, miR-296, and miR-221/222, functional studies were performed in ECs using a gain-of-function approach ( Figure 1B ). As reported in Figure 1C , ECs overexpressing pre-miR-222, but not pre-miR-221, pre-miR-126, or pre-miR-296 (data not shown), failed to undergo proliferation and to migrate in response to IL-3, compared with negative controls. Similar results were obtained on bFGF stimulation as well (data not shown), suggesting that miR-222 is specifically controlling vascular growth.
STAT5A Is a Novel miR-222 Target in ECs Challenged With IL-3 and bFGF
bFGF and IL-3 trigger vascular EC morphogenesis by activating the STAT5 signaling pathway. 5 According to various prediction software (miRBase-MicroCosm version v5 and miRecords), STAT5A is a predicted miR-222 and miR-221 target ( Figure 2A) . Thus, biochemical studies were performed using a gain-of-function approach ( Figure 1B ). As shown in Figure 2B , despite the fact that STAT5A was also a predicted target of miR-221, miR-222, but not miR-221, overexpression was associated with down-regulation of STAT5A protein levels and, consistently with the biological relevance of this correlation, overexpressing STAT5A, lacking the endogenous 3Ј-untranslated region (UTR), rescued cyclin D1 expression ( Figure 2C ) and EC functions, such as proliferation and migration ( Figure 2D ). No effect of miR-126 was observed on STAT5A in our system ( Figure 2B ). To validate our data, biochemical and functional studies using a loss-offunction approach were performed (supplemental Figure II) . As shown in supplemental Figure IIB through IID, a further increment in STAT5A expression was detected by expressing anti-miR-222 but not anti-miR-221 (supplemental Figure  IIA) . Consistently, both cell proliferation or cell migration (supplemental Figure IIC) were further improved in the presence of IL-3. However, even in the presence of slightly increased expression of STAT5A, no biological effect was observed following anti-miR-222 transfection in absence of IL-3, possibly because the anti-miR cannot decrease miR-222 levels to rescue IL-3 effect. Similar results were obtained when the experiments were performed in the presence of bFGF (data not shown). Finally, by knocking down STAT5A expression in ECs (supplemental Figure III) , by RNA interference, we were able to reproduce miR-222 biological effects. To validate these data, STAT5A and miR-222 expression was evaluated in quiescent ECs following bFGF or IL-3 stimulation. Increased STAT5A protein, but not mRNA levels ( Figure 3A , left, and supplemental Figure IVA) , and decreased miR-222 ( Figure 3A , right) expression were detected. In parallel, increased cyclin D1 protein levels ( Figure  3A ) and cell proliferation, as well as cell migration ( Figure  3B ), were observed. No change in c-Kit and p27
Kip1 were observed ( Figure 3A and supplemental Figure IVB) . To ascertain the direct effect of miR-222 on STAT5A-3Ј-UTR, the luciferase reporter vectors containing the wild-type fulllength STAT5A-or STAT5B-3Ј-UTR were transfected in ECs. An increased luciferase activity was detected in STAT5A-3Ј-UTR expressing ECs exposed to both bFGF or IL-3 ( Figure 3C ). Decreased gene reporter activity was observed when the same wild-type construct was transfected in HEK293 cells (an easily transfectable miR-222 empty recipient) and when overexpression of miR-222 was forced (supplemental Figure V) . However, increased luciferase activity was observed when the same HEK293 cells were transfected with a construct carrying a mutant STAT5A-3Ј-UTR following miR-222 overexpression (supplemental Figure VB) . Nevertheless, pre-miR-221 and pre-miR-222 were able to act on their specific targets. Indeed, when HEK293 cells were transfected with constructs carrying p27 kip1 -3Ј-UTR or c-Kit-3Ј-UTR and overexpressing pre-miR-221 or pre-miR-222, a decreased luciferase activity was detected (supplemental Figure VC) . STAT5A is also a predicted miR-125a-3p target (see the prediction software above). As shown in supplemental Figure VIA , miR-125a-3p was downregulated by inflammatory stimuli. However, we failed to detect changes in STAT5A or cyclin D1 protein expression and in luciferase activity following IL-3 treatment in miR125a-3p-overexpressing cells (supplemental Figure VIB and VIC), further indicating that STAT5A is mostly regulated by miR-222 during inflammation-mediated neoangiogenesis. Together, these findings led us to focus our in vivo investigations on miR-222.
miR-222 Controls In Vivo Neoangiogenesis and Intraplaque Vessel Formation by Targeting STAT5A
The role of miR-222 in regulating vessel growth was evaluated in vivo by injecting severe combined immunodeficient mice with Matrigel plugs containing bFGF or IL-3 and ECs overexpressing miR-222 or its negative control. As shown in Figure 4A , human CD31-positive ECs, but no functional Kip-1 , and ␤-actin expression. C, ECs cultured with IL-3 were transfected with pre-miR negative control (neg c) or pre-miR-222, only or in combination with a STAT5A expression vector (5A). 48 hours later, cell extracts were prepared and subjected to SDS-PAGE, and the filters were immunoblotted (IB) with the indicated antibodies. D, Cell proliferation (upper) and cell migration (lower) assays were performed in ECs treated as described in C (for B, C, and D, *PϽ0.05, experimental versus control values).
vessels (no tubular structures containing erythrocytes into the lumen), were detected in Matrigel plugs injected with miR-222-overexpressing cells, compared with negative controls ( Figure 4A) . Consistently, biochemical analysis on ECs from the same Matrigel plugs revealed almost undetectable levels of STAT5A protein ( Figure 4B ). Once more, we did not detect any change in c-Kit or p27
Kip1 expression following miR-222 overexpression ( Figure 4B ). In addition, the finding that ECs, depleted of endogenous STAT5A by RNA interference, injected in severe combined immunodeficient mice replicated miR-222 overexpressing phenotype further sustains the above data (supplemental Figure VII) . Conversely, a rescue of angiogenesis followed STAT5A exogenous expression in miR-222-overexpressing ECs ( Figure 4A ). Instead, reduced proliferation was observed in plugs injected with miR-222-overexpressing ECs, as measured by Ki67 immunostaining (supplemental Figure VIII) .
Inflammatory cells stringently control intraplaque neovascularization and lesion progression. 1,2 IL-3, like bFGF, is released in neointima microenvironment. 3 Thus, the biological relevance of miR-222 in regulating plaque progression was investigated by isolating human ECs from normal and atherosclerotic samples. As already reported, 14,15 miR-222 is highly expressed in CD31-positive ECs recovered from normal vessels ( Figure 5A ). Conversely, from early to advanced lesions, a progressively decreased expression of miR-222, but not of miR-17-5p, was detected ( Figure 5A ; for atherosclerotic lesion description, please see supplemental material). Tissue-specificity of miR-222 expression is provided by the following observations: (1) no anti-␣-smooth muscle actin staining was revealed in the recovered ECs from advanced lesions, (2) no changes in miR-222 expression could be detected in SMCs exposed to IL-3 or bFGF, and (3) the level of miR-222 was almost undetectable in unstimulated or macrophage colony stimulating factor-stimulated peripheral blood mononuclear cells ( Figure 5B ). Similar results were obtained by lipopolysaccharide stimulation (data not shown). The possibility that miR-222 expression might negatively control neovascularization is sustained by the proliferation rate of ECs lining vessels inside the advanced lesions (positive immunostaining for Ki67) ( Figure 5C ) and by the increased number of vessels in low miR-222 expressing plaques ( Figure 5D ).
ECs recovered from normal vessels and from lesions at different stages of progression were also evaluated for STAT5A expression. Indeed, STAT5A is barely detectable in nonproliferating normal vessel, and its expression increases from early ( Figure 5A , lane 1) to advanced lesions ( Figure  5A, lanes 2 and 3) . A positive STAT5A immunostaining was also detected in vessels from advanced lesions compared with normal tissues (supplemental Figure IX) . Moreover, the finding that no changes in c-Kit and p27
Kip1 protein expression could be detected ( Figure 5A ) again identifies STAT5A as the main regulator of neovascularization, which is mostly regulated posttranscriptionally by miR-222.
Discussion
Atherosclerotic lesion progression requires intraplaque neovascularization, 1,2 and the inflammatory cells contained in the neointima mainly contribute to this process by releasing cytokines and growth factors, such as IL-3 and bFGF. [1] [2] [3] Although these mediators are known to control a number of different genes, very little is known about their effects in regulating gene expression and translation during vessel formation. Recently, miRNAs have been recognized as negative regulators of gene expression. 10 -12 Key targets of Kip-1 , p57 Kip2 , cyclin D1, and ␤-actin expression as indicated (left). Fold expression of miRNAs was representative of 3 independent experiments performed in triplicate. B, Proliferation (right) and migration (left) assays of ECs treated as above. C, pmiR vector or pmiR-3Ј-UTR STAT5A or pmiR-3Ј-UTR STAT5B luciferase constructs were transfected into quiescent or IL-3-or bFGF-treated ECs. The relative luciferase activity is reported (*PϽ0.05, experimental versus control values).
miRNAs have been identified in cancer cells, 13, 16, 17 but relatively little is known about miRNAs involved in vascular diseases. So far, only a few specific miRNAs recognized as proangiogenic or antiangiogenic miRNAs have been described. 10 -13 Among the latter, miR-221/miR-222 have been reported to negatively regulate vessel formation, by targeting c-Kit. 14 In addition, miR-221/miR-222 have been shown to act as crucial modulators of SMC proliferation by targeting p27
Kip1 and p57 Kip2 . 15 However, the impact of hypoxia, inflammation, cardiovascular risk factors, or laminar sheer stress on the expression profile of miRNAs in vascular cell biology is still under investigation. 18 -20 Indeed, very recent data demonstrated that in pathological settings, linked to inflammation, growth factors, or cytokines, can differentially regulate miRNA expression in ECs. 21, 22 In the present study, we provide evidence that miR-222 is the main regulator of vascular cell biology in an inflammatory microenvironment containing IL-3 or bFGF. Moreover, we identify STAT5A as a novel miR-222 target involved in inflammation-mediated neovessel formation.
The 2 highly homologous proteins, STAT5A and STAT5B, act as signaling components between the plasma membrane and the nucleus and as transcriptional factors by regulating the expression of genes involved in proliferation, survival, and differentiation. 6 STAT5A and STAT5B show a high degree of conservation. However, these 2 homologous proteins exert nonredundant functions during developmental processes and in the adult cardiovascular system. 7 For instance, STAT5B, unlike STAT5A, seems to play a role in balloon injury-induced neointima formation 8 and to regulate gene expression in diabetes-associated vascular disease. 9 Conversely, STAT5A seems to be involved in postmyocardial infarction remodeling. 23 We found that during vessel growth, STAT5A, but not STAT5B, is posttranscriptionally regulated by miR-222, therefore defining an additional nonredundant function for STAT5 proteins.
Despite the fact that miR-222 and miR-221 contain the same seed and that the expression of both miRNAs was reduced in ECs following IL-3 or bFGF treatment, miR-221 did not appear to be biologically relevant for inflammationmediated vascular growth (ie, proliferation, migration, STAT5A and cyclin D1 expression, and STAT5A binding 3Ј-UTR). Different biological activities between miR-221 and miR-222 were previously observed in a model of liver tumorigenesis, in which miR-221, but not miR-222, was able to accelerate tumors in mice. 24 One can make the hypothesis that specific miRNAs activities between miR-221 and miR-222 depend on sequence differences present downstream of the common seed in the 2 miRNAs. In fact, it has been predicted and/or demonstrated that other nucleotides, apart from the seed sequence, can be relevant for miRNA activity as discussed in Filipowicz et al, 25 Bartel, 26 and elsewhere. [27] [28] [29] However, functional evaluation of each specific nucleotide downstream of the seed can be performed only by a complete mutagenesis analysis.
miR-222 was shown to be down-modulated in endometrioid and clear cell ovarian carcinomas but not in the serous type of the same tumor. 30 These results indicate that miRNA ECs transfected with pre-miR negative control (neg c) or premiR-222 oligonucleotide, only or in combination with a STAT5A expression vector (5A), were recovered 4 days after implantation in severe combined immunodeficient mice. Histological (magnification ϫ10; left) and immunofluorescence (magnification ϫ20; right) analyses are reported. Immunofluorescence stains were performed with an anti-human CD31 antibody (green) and the 4Ј,6-diamidino-2-phenylindole DAPI nuclear marker (blue). Quantification of neoformed vessels observed in histological analysis was expressed as percentageϮSD of the vessel area to the total Matrigel area. Scale bars indicate 200 m for histological analysis and 50 m for immunofluorescence analysis. B, ECs, recovered by CD31-positive magnetic sorting from the Matrigel plugs described above, were analyzed by qRT-PCR and Western blotting for miR-222 and for c-Kit, STAT5A, p27 Kip1 , vascular endothelial-cadherin (VE-cadherin), ␣-smooth muscle actin (SMA), and ␤-actin expression, respectively. Fold expression of miRNAs was representative of 3 independent experiments performed in triplicate (*PϽ0.05, experimental versus control values).
activity can be very dependent on the cellular environment and that miRNA-mediated control can display specificity in terms of functional restriction to a particular cellular context or differentiation pathway. 31, 32 Probably, this could be the reason why we were not able to see an effect of miR-222 on c-Kit in our experimental conditions. Moreover, the fact that we did not observe modulations of miR-222 on p27 Kip1 , even if this is a validated miR-222 target, with a proven role in SMC proliferation and cell cycle, 15 sustains the possibility that miR-222 effects and/or its targets are cell type dependent. Understanding the complex network of miRNAs and their targets may provide new tools to develop therapeutic strategies, not only to enhance neovascularization of ischemic tissues, but also to hamper pathological vessel growth. Indeed, in conditions such as atherosclerosis, intimal angiogenesis occurs as part of the adaptive changes known as vasculature remodeling. 1,2 Our finding demonstrating that miR-222 acts as an antiangiogenic miRNA, by controlling STAT5A expression, provides promising perspectives to interfere with deregulated vascular remodeling and atherosclerotic disease progression. 
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